Interleukin-6 in Multiple Myeloma: Correlation with Disease Activity and Ki-67 Proliferation Index

References

• Durie B.G.M., Salmon S.E. A clinical staging system for myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842
   PubMed Web of Science ®Google Scholar
• Fritz E., Ludwig H., Kundi M. Prognostic relevance of cellular morphology in multiple myeloma. Blood 1984; 63: 1072–1079
   PubMed Web of Science ®Google Scholar
• Greipp P.R., Raymond N.M., Kyle R.A., O'Fallon W.M. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305–310
   PubMed Web of Science ®Google Scholar
• Bartl R., Frisch B., Burkhardt R., Fateh-Moghadam A., Mahl G., Gierster P., Sund M., Kettner G. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br. J. Haematol. 1982; 51: 361–375
   PubMed Web of Science ®Google Scholar
• Durie B.G.M., Salmon S.E., Moon T. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 1980; 55: 364–372
   PubMed Web of Science ®Google Scholar
• Greipp P.R., Katzmann J.A., OtFallon W.M., Kyle R.A. Value of β2 microglobulin level and plasma cell labeling induces as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219–223
   PubMed Web of Science ®Google Scholar
• Durie B.G.M., Stock-Novack D., Salmon S.E., Finley P., Beckord J., Crowley J., Coltman C.A. Prognostic value of pretreatment serum β2 microglobulin in myeloma: a southwest oncology group study. Blood 1990; 75: 823–830
   PubMed Web of Science ®Google Scholar
• Cuzick J., Cooper E.H., MacLennan I.C.M. The prognostic value of serum β2 microglobulin compared with other presentation features in myelomatosis. Br. J. Cancer 1985; 52: 1–6
   PubMed Web of Science ®Google Scholar
• Reibenegger G., Krainer M., Herold M., Ludwig H., Wachter H., Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res. 1991; 51: 6250–6253
   PubMed Web of Science ®Google Scholar
• Bataille R., Boccadoro M., Klein B., Durie B., Pileri A. C-reactive protein and β2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–737
   PubMed Web of Science ®Google Scholar
• Ludwig H., Nachbaur D.M., Fritz E., Krainer M., Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991; 11: 2194–2195
   Google Scholar
• Hack C.E., De Groot E.R., Felt-Bersma R.J.F., Nuijens J.H., Strack von Schijndel R.J.M., Eerenberg-Belmer A.J.M., Thijs L.G., Aarden L.A. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704–1710
   PubMed Web of Science ®Google Scholar
• Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon β2/B cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA 1989; 84: 7251–7255
   Web of Science ®Google Scholar
• Ikebuchi K., Wong G.G., Clark S.C., Ihle J.N., Hirai Y., Ogawa M. Interleukin-6 enhancement of interleukin-3 dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA 1987; 84: 9035–9039
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1–10
   PubMed Web of Science ®Google Scholar
• Jourdan M., Bataille R., Seguin J., Zhang X.G., Chaptal P.A., Klein B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis and Rheumatism 1990; 33: 398–401
   PubMed Web of Science ®Google Scholar
• Yoshizaki K., Matsuda T., Nishimoto N., Kuritani T., Taeho L., Aozasa K., Nakahata T., Kawai H., Tagoh H., Komori T., Kishimoto S., Hirano T., Kishimoto T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74: 1360–1367
   PubMed Web of Science ®Google Scholar
• Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., Sato K., Shimizu M., Maini R., Feldmann M., Kishimoto T. Excessive production of interleukin-6/B cell stimulatory factor 2 in rheumatoid arthritis. Eur. J. Immunol. 1988; 18: 1797–1801
   PubMed Web of Science ®Google Scholar
• Van Snick J., Vink A., Cayphas S., Uyttenhove C. Interleukin-HPI, a T cell derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J. Exp. Med. 1987; 165: 641–649
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O.O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332: 83–85
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Kyle R.A., Greipp P.R. Smoldering multiple myeloma. New Engl. J. Med. 1980; 302: 1347–1349
   PubMed Web of Science ®Google Scholar
• Chronic Leukemia-Myeloma Task Force of the National Cancer Institute. Proposed guidelines for protocol studies; II. Plasma cell myeloma. Cancer Chemotherapy Reports 1968; 1: 17
   Google Scholar
• Ludwig H. Multiples Myelom; Diagnose, Klinik unci Therapie, 1st edn. Springer-Verlag, Berlin 1982; 152–154
   Google Scholar
• Thaler J., Denz H., Gattringer C., Glassl H., Lechleitner M., Dietze O., Huber H. Diagnostic and prognostic value of immunohistological bone marrow examination: results in 212 patients with lymphoproliferative disorders. Blut 1987; 54: 213–222
   PubMedGoogle Scholar
• Nachbaur D.M., Herold M., Maneschg A., Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Annu. Hematol. 1991; 62: 54–58
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 1983; 65: 55–62
   PubMed Web of Science ®Google Scholar
• Cordell J.L., Falini B., Erber W.N., Ghosh A.K., Abdulaziz Z., MacDonald S., Pulford K.A.F., Stein H., Mason D.Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem. 1984; 32: 219–229
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X.G., Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyspasias. J. Clin, Inv. 1989; 84: 2008–2011
   PubMed Web of Science ®Google Scholar
• Portier M., Rajzbaum G., Zhang X.G., Attal M., Rusalen C., Wijdenes J., Mannoni P., Mraninchi D., Piecharczyk M., Bataille R., Klein B. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur. J. Immunol. 1991; 21: 1759–1762
   PubMed Web of Science ®Google Scholar
• Durie B.G.M., Vela E.E., Frutiger Y. Macrophages as an important source of paracrine IL-6 in myeloma bone marrow. Current Topics Microbiol. Immunol. 1990; 166: 33–36
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Gregoretti M.G., Gaidano G., Gaboli M., Schena M., Zallone A.Z., Marchisio P.C. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688–2693
   PubMed Web of Science ®Google Scholar
• Shimizu S., Yoshioka R., Hirose Y., Sugai S., Tachibana J., Konda S. Establishment of two interleukin-6 (B cell stimulatory factor 2/interferon-β2) dependent human bone marrow derived myeloma cell lines. J. Exp. Med. 1989; 169: 339–344
   PubMed Web of Science ®Google Scholar
• Ishikawa H., Tanaka H., Iwato K., Tanabe O., Assaoku H., Nobuyoshi M., Yamamoto I., Kawano M., Kuramoto A. Effect of glucocorticoids on the biological activities of myeloma cells: inhibition of interleukin-1β osteoclast activating factor-induced bone resorption. Blood 1990; 75: 715–720
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.Y.G., Jourdan M., Boiron J.M., Portier M., Lu Z.Y., Wijdenes J., Brochier J., Bataille R. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur. Cytokine Network 1990; 1: 193–201
   PubMedGoogle Scholar
• Herrmann F., Andreeff M., Gruss H.J., Brach M.A., Lübbert M., Mertelsmann R. lnterleukin-4 inhibits growth of multiple myeloma by suppressing interleukin-6 expression. Blood 1991; 78: 2070–2074
   PubMed Web of Science ®Google Scholar
• Cordell J., Falini B., Erber W.N., Ghosh A.K., Abdulaziz Z., MacDonald S., Pulford K.A.F., Stein H., Mason D.Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem. 1984; 32: 219–229
   PubMed Web of Science ®Google Scholar